Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
QDEL Logo

Quidelortho Corp

QDEL

In Vitro & In Vivo Diagnostic Substances

Mkt Cap

$2.947B

PE

-1.67

Debt

$2.402B

Cash

$79M

EV

$5.27B

FCF

-$118.8M

Market Cap

$2.947B

P/E Ratio

-1.67

Debt

$2.402B

Cash

$79M

EV

$5.27B

FCF

-$118.8M
Charts data: {"Earnings":[{"time":"2021-01-02","value":810300000},{"time":"2022-01-01","value":704200000},{"time":"2022-12-31","value":548700000},{"time":"2023-12-30","value":-10100000}],"Sales":[{"time":"2021-01-02","value":1661700000},{"time":"2022-01-01","value":1698600000},{"time":"2022-12-31","value":3266000000},{"time":"2023-12-30","value":2997800000}],"Net Margins":[{"time":"2021-01-02","value":0.48763314677739666},{"time":"2022-01-01","value":0.41457671023195575},{"time":"2022-12-31","value":0.1680036742192284},{"time":"2023-12-30","value":-0.003369137367402762}],"Assets":[{"time":"2022-01-01","value":2430400000},{"time":"2022-12-31","value":8855800000},{"time":"2023-12-30","value":8563100000}],"Stockholders Equity":[{"time":"2021-01-02","value":1332700000},{"time":"2022-01-01","value":1929400000},{"time":"2022-12-31","value":4934600000},{"time":"2023-12-30","value":5005900000}],"ROE":[{"time":"2021-01-02","value":0.6080138065581151},{"time":"2022-01-01","value":0.3649839328288587},{"time":"2022-12-31","value":0.11119442305354031},{"time":"2023-12-30","value":-0.002017619209332987}],"ROA":[{"time":"2022-01-01","value":0.37277814351547073},{"time":"2022-12-31","value":0.09527089591002506},{"time":"2023-12-30","value":0.01624411720054653}]}

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

Sector

  • IDXX Logo

    IDXX

  • LNTH Logo

    LNTH

  • MYGN Logo

    MYGN

  • NEOG Logo

    NEOG

  • NTLA Logo

    NTLA

In the chart Earnings are multiplied by this value.

Earnings Growth -91%
Earnings Stability -25%


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years01-202101-202212-202212-2023TTM
Net Margin49%41%17%-0.34%-62%
ROA-37%9.5%1.6%-26%
ROE61%36%11%-0.2%-53%

What is the average Net Margin?

The average Net Margin over the past 5 years is +8.23%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is -17.14%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is +5.58%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is -7.9%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is +5.46%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is -11.32%.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years01-202101-202212-202212-2023TTM
Debt FCF-0.003.8436.14-20.22
Debt Equity-0.000.580.510.73
MIN
Graham Stability----1.5%-1.5%

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -20.22.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is 32.30.

What is the Graham’s Stability?

Graham’s Stability measure stands at -0.01.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years01-202112-2022Trend
Revenue22%-8.2%-5.2%
Net Income---9%
Stockholders Equity55%1.4%-22%
FCF-50%-90%-41%

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is -.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -5.22%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -8.99%.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is -.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -21.66%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -40.66%.